Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Go back to Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 69.06 +0.51 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.55 | 52 Week High | $18.39 | |||
| Open | $69.34 | 52 Week Low | $6.96 | |||
| Day High | $69.81 | P/E | N/A | |||
| Day Low | $68.27 | EPS | $-0.58 | |||
| Volume | 685,097 | |||||
